Name
Abion Inc.
Company Description
ABION, based in South Korea, develops innovative Best-In-Class and First-In-Class lung cancer drugs. Our lead program, Vabametkib, a selective TKI for MET NSCLC in Phase 2 trials, offers an excellent safety profile for patients with MET mutations. Additionally, we're developing ABN501, targeting Claudin-3 in small cell lung cancer (SCLC), showcasing our commitment to addressing unmet needs in oncology. Launched in 2024, our ABN202 antibody-cytokine platform technology utilizes interferon-beta to enhance lung cancer antibodies' efficacy by leveraging both the adaptive and innate immune systems
Website
Product Categories (5)
Lung Cancer, Antibodies, Biomarkers, Biotechnology, Drug Development
First Time Exhibitor
Yes
Phone (If provided, phone will display online and in-print)
02-600-676-57
Address
Seoul,
United States
United States
Twitter
Recognition
